This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
Save the dateMarch 17–19, 2025 | Milan, Italy

Laura Lane
VP - Venture Sciences (Europe) at Eli Lilly & Co


Laura Lane, PhD, is currently VP Lilly Ventures and the regional Head of Lilly Ventures for Eli Lilly & Company. Her focus is on Lilly’s venture capital strategy for Europe covering both direct investments into biotech and life science companies, and fund-of-fund relationships and investments, as well as supporting wider external innovation efforts across Lilly.

Laura is a PhD-trained scientist with diverse scientific, business, transaction and operational experience. Her experience spans: venture capital; technology transfer; the charity sector; founding and leading biotech and life science start-ups; life science consulting as well as now pharma. Prior to Lilly, Laura was part of the investment team at Advent Life Sciences; selected investments included Highlight Therapeutics (Madrid, Spain), MiroBio (Oxford, UK) (acquired by Gilead Sciences August 2022), PIC Therapeutics (Boston, USA) and Proximie (London, UK). Prior to Advent, Laura held CEO and COO positions at several UK life science/biotech companies in Birmingham, Oxford & London.

Laura gained her masters and doctorate from the University of Cambridge and currently serves on the boards of the non-profit Collaborative Community against Coronavirus (3CCorona) CIC and the UK’s BioIndustry Association (BIA).

Agenda Sessions

  • New generation of life science venture investing